Translational Psychiatry

Intranasal Delivery of shRNA Edits to Silence 5-HT2A Receptor Shows Promise in Enhancing Memory and Alleviating Anxiety

Retrieved on: 
Thursday, March 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Genetics, Clinical Trials, Depression, Brain, Dementia, Rat, BBB, Memory, Central nervous system, Public, RNA, Mouse, Traffic barrier, Anxiety, Translational Psychiatry, MCI, Neurological disorder, DSM-IV codes, HTR2A, Intrinsic termination, Therapy, Optimism, Cas9, Vaccine

In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.

Key Points: 
  • In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.
  • Neurological disorders such as Mild Cognitive Impairment (MCI), depression, and anxiety disorders pose significant challenges to public health worldwide.
  • In this study, the researchers designed shRNA sequences to specifically target and silence the human HTR2A gene, which is associated with anxiety and memory.
  • The ability to bypass the blood-brain barrier using intranasal delivery opens up new avenues for precision-based therapeutics in neurological disorders."

DSM comments on a new study linking COVID-19 to increased risk of neurological disorders - Omega 3s to be a potential solution

Retrieved on: 
Tuesday, November 29, 2022
COVID-19, Nature Medicine, Red blood cell, International Society, Cerebrovascular disease, Eicosapentaenoic acid, Brain, EPA, Nutrition, DSM, Systematic review, Risk, Cognition, Knowledge, Dementia, DHA, Retina, Inflammation, Nature Reviews Immunology, Diabetes, Memory, Depression, Meta-analysis, DSM (company), COVID, Translational Psychiatry, Research, The American Journal of Clinical Nutrition, Euronext Amsterdam, Oxidative stress, Animal, Smoking, Infection, Obesity, Pharmaceutical industry, Dietary supplement, Health, Behavior, Psychiatry, Immunity, Science

[ii] The neurological conditions reported include cerebrovascular disease, cognition and memory disorders, sensory disorders and mental health conditions.

Key Points: 
  • [ii] The neurological conditions reported include cerebrovascular disease, cognition and memory disorders, sensory disorders and mental health conditions.
  • Risk of neurologic conditions related to long COVID were elevated even in people who were not hospitalized with acute COVID-19 infection.
  • Researchers are working hard to understand the mechanisms by which COVID-19 infection leads to the neurological disorders observed in long COVID.
  • Royal DSM is a global, purpose-led company in Health, Nutrition & Bioscience, applying science to improve the health of people, animals and the planet.

First Blood Test to Diagnose Bipolar Disorder

Retrieved on: 
Thursday, June 9, 2022
Biomarker, Outpatient clinic (hospital department), Translational Psychiatry, Research, Mental health, Cyclothymia, Bipolar disorder, RNA editing, Artificial intelligence, Depression, Depressive, University, RNA, Professor, Partnership, Psychiatry, Innovation, Blood, Gene, IVDR, Conditional sentence, European Institute, Patient, Lists of diseases, Gene expression, Nature (journal), Wilfrid Sellars, UD, Diagnosis, Center, Department, BD, Technology, Medical device, Pharmaceutical industry, Synlab Group, Nature

MONTPELLIER, France and PARIS, June 9, 2022 /PRNewswire/ -- Alcediag, a French company specializing in precision psychiatry and a pioneer in biological diagnosis in mental health, announces the publication, in Nature: Translational Psychiatry, of a study that identified a panel of six blood biomarkers, major hallmarks of bipolar disorder.

Key Points: 
  • These results, recently published in the leading scientific journal Nature, have led to the development of the first diagnostic blood test for this disorder that affects more than 60 million people worldwide.
  • While the number of people suffering from depression is estimated at 300 million worldwide, up to 40% of them could actually be affected by bipolar disorder.
  • Yet, the management and treatments for bipolar disorder and depression differ significantly, making timely and reliable diagnosis paramount.
  • For the first time, the study led by Alcediag, including a cohort of 410 subjects, provides such a reliable, accurate test capable of differentiating the depressive phases of bipolar disorder from unipolar depression.

Feinstein Institutes’ studies show CTE-linked tau protein may contribute to psychosis in Alzheimer's disease

Retrieved on: 
Monday, February 28, 2022
Other Health, Research, Managed Care, General Health, Mental Health, Infectious Diseases, Hospitals, Clinical Trials, Science, Medical Supplies, Other Science, Health, Genetics, Medical research, Molecular medicine, The New England Journal of Medicine, Chronic traumatic encephalopathy, PET, Psychosis, Hallucination, CTE, Feinstein Institute for Medical Research, Northwell Health, Autoimmunity, Rapunzel's Tangled Adventure (season 2), Mouse, Medicine, NFL, Pathology, Dopamine, Mental health, Tau, National Football League, Feinstein, Aggression, LinkedIn, Multimedia, Science, Alzheimer's disease, Brain, AD, Cancer, Patient, Credit, Research, Behavior, Injury, Delusion, CEO, Â, Pharmaceutical industry, Medical imaging, Translational Psychiatry, MD, Dementia

The findings suggest future investigations into how dopamine neurotransmission and abnormal tau proteins interact in psychosis in Alzheimer's disease and how modulation of this interaction could be a treatment target.

Key Points: 
  • The findings suggest future investigations into how dopamine neurotransmission and abnormal tau proteins interact in psychosis in Alzheimer's disease and how modulation of this interaction could be a treatment target.
  • Millions living with Alzheimers disease need more targeted, effective treatments, which requires a better understanding of the disease mechanisms, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes.
  • The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State.
  • For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn .